HUTCHMED Receives Breakthrough Therapy Designation from China’s NMPA September 14, 2021 Auto Bot News 0 HUTCHMED’s amdizalisib (HMPL-689) received breakthrough therapy designation for the treatment of a subtype of non-Hodgkin’s lymphoma.
